Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$13 Mln
Revenue (TTM)
$2 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.5
Industry P/E
28.02
EV/EBITDA
14.8
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.2
Face value
--
Shares outstanding
11,574,400
CFO
$-896.75 Mln
EBITDA
$-853.70 Mln
Net Profit
$-951.33 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
TherapeuticsMD (TXMD)
| 30.2 | -22.8 | 25.8 | -41.7 | -51.7 | -55.2 | -44.4 |
|
BSE Sensex
| 4.9 | 0.4 | 6.7 | 6.3 | 16.2 | 18.3 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|
|
TherapeuticsMD (TXMD)
| -61.5 | -59.7 | -70.2 | -50.0 | -36.5 | -36.8 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
TherapeuticsMD (TXMD)
|
1.1 | 12.6 | 1.8 | -2.1 | -182.2 | -7.8 | -- | 0.5 |
| 17.6 | 4,328.3 | 459.4 | 206.8 | 25.6 | 68.3 | 21.6 | 11.3 | |
| 8.0 | 3,640.5 | 2,830.2 | -13.1 | 11.5 | -- | -- | 86.1 | |
| 102.9 | 4,957.6 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 93.2 | |
| 54.4 | 10,547.7 | 2,937.8 | 523.9 | 23.2 | 9.3 | 20.4 | 1.8 | |
| 43.5 | 7,923.7 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 75.5 | 7,569.5 | 685.5 | 132.9 | 15.6 | 20.1 | 62.1 | 11.1 | |
| 13.3 | 6,684.9 | 4,427.0 | 373.0 | -0.7 | 5.8 | 17.9 | 1.1 | |
| 84.6 | 4,123.2 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.4 | 2.2 | |
| 8.9 | 10,410.5 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD... and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. Address: 951 Yamato Road, Boca Raton, FL, United States, 33431 Read more
Executive Chairman
Governor Thomas G. Thompson
Executive Chairman
Governor Thomas G. Thompson
Headquarters
Boca Raton, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of TherapeuticsMD Inc (TXMD) stood at $ 43 Mln as on 31-Mar-25
The share price of TherapeuticsMD Inc (TXMD) is $1.12 (NASDAQ) as of 24-Jun-2025 11:41 EDT. TherapeuticsMD Inc (TXMD) has given a return of -51.73% in the last 3 years.
TherapeuticsMD Inc (TXMD) has a market capitalisation of $ 13 Mln as on 23-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of TherapeuticsMD Inc (TXMD) is 0.48 times as on 23-Jun-2025, a 90% discount to its peers’ median range of 4.74 times.
Since, TTM earnings of TherapeuticsMD Inc (TXMD) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the TherapeuticsMD Inc (TXMD) and enter the required number of quantities and click on buy to purchase the shares of TherapeuticsMD Inc (TXMD).
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. Address: 951 Yamato Road, Boca Raton, FL, United States, 33431
The CEO & director of Governor Thomas G. Thompson. is TherapeuticsMD Inc (TXMD), and CFO & Sr. VP is Governor Thomas G. Thompson.
There is no promoter pledging in TherapeuticsMD Inc (TXMD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,059
|
|
|
1,029
|
|
|
762
|
|
|
761
|
|
|
676
|
|
|
507
|
|
|
433
|
|
|
414
|
|
|
368
|
| TherapeuticsMD Inc. (TXMD) | Ratios |
|---|---|
|
Return on equity(%)
|
-7.8
|
|
Operating margin(%)
|
-182.24
|
|
Net Margin(%)
|
-114.07
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of TherapeuticsMD Inc (TXMD) was $0 Mln.
$0.01
(
